 DALLAS--BUSINESS WIRE--Taysha Gene Therapies, Inc. Nasdaq: TSHA, a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations, today announced that it has received both rare pediatric disease and orphan drug designations from the U.S. Food and Drug Administration FDA for TSHA-103, an AAV-9-based gene therapy in development for SLC6A1 